Srinivas Akkaraju, Director at Mineralys Therapeutics, Inc. (MLYS), bought 1,176,470 shares at $25.50 ($30.0M) on 2025-09-04, disclosed to the SEC on 2025-09-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.50 | 588,235 | $15.0M | 50.0% |
| 2 | $25.50 | 588,235 | $15.0M | 50.0% |
| Total | $25.50 avg | 1,176,470 | $30.0M | 100% |
| Filing → |
| KLRS | BUY | 2026-05-22 | $1.2M | — | Filing → |
| ALMS | BUY | 2026-01-13 | $10.0M | — | Filing → |
| SRRK | BUY | 2025-12-16 | $1.9M | — | Filing → |